Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors. 2017

Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.

Phosphatidylinositol 3-kinase (PI3K) is a pivotal regulator of intracellular signaling pathways and considered as a promising target in the development of a therapeutic treatment of cancer. Among the different PI3K subtypes, the PIK3CA gene encoding PI3K p110α is frequently mutated and overexpressed in majority of human cancers. Therefore, the inhibition of PI3Kα has been considered to be an efficient approach for the treatment of cancer. In this study, two series compounds containing hydrophilic group in imidazo[1,2-a]pyridine and quinazolin-4(3H)-one were synthesized and their antiproliferative activities against five cancer cell lines, including HCT-116, SK-HEP-1, MDA-MB-231, SNU638 and A549, were evaluated. Compound 1i with most potent antiproliferative activity was selected for further biological evaluation. PI3K kinase assay showed that 1i has selectivity for PI3Kα distinguished from other isoforms. The western blot assay indicated that 1i is more effective than HS-173, an imidazopyridine-based PI3Ka inhibitor, in reducing the levels of phospho-Akt. All these results suggested that 1i is a potent PI3Kα inhibitor and could be considered as a potential candidate for the development of anticancer agents.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
October 2015, Chemical biology & drug design,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
March 2020, Journal of medicinal chemistry,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
May 2015, ACS medicinal chemistry letters,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
April 2021, European journal of medicinal chemistry,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
April 2015, Journal of enzyme inhibition and medicinal chemistry,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
January 2007, Bioorganic & medicinal chemistry,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
September 2021, Archiv der Pharmazie,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
April 2024, Drug development research,
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
September 2019, Molecules (Basel, Switzerland),
Yan-Hua Fan, and Wei Li, and Dan-Dan Liu, and Meng-Xuan Bai, and Hong-Rui Song, and Yong-Nan Xu, and SangKook Lee, and Zhi-Peng Zhou, and Jian Wang, and Huai-Wei Ding
September 2021, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!